Abstract:Gastrointestinal (GI) cancer is one of the most common malignancies, and a leading cause of cancer-related death worldwide. However, molecular targeted therapies are still lacking, leading to poor treatment efficacies. As an important layer of epigenetic regulation, RNA N6-Methyladenosine (m6A) modification is recently linked to various biological hallmarks of cancer by orchestrating RNA metabolism, including RNA splicing, export, translation, and decay, which is partially involved in a novel biological process termed phase separation. Through these regulatory mechanisms, m6A dictates gene expression in a dynamic and reversible manner and may play oncogenic, tumor suppressive or context-dependent roles in GI tumorigenesis. Therefore, regulators and effectors of m6A, as well as their modified substrates, represent a novel class of molecular targets for cancer treatments. In this review, we comprehensively summarize recent advances in this field and highlight research findings that documented key roles of RNA m6A modification in governing hallmarks of GI cancers. From a historical perspective, milestone findings in m6A machinery are integrated with a timeline of developing m6A targeting compounds. These available chemical compounds, as well as other approaches that target core components of the RNA m6A pathway hold promises for clinical translational to treat human GI cancers. Further investigation on several outstanding issues, e.g. how oncogenic insults may disrupt m6A homeostasis, and how m6A modification impacts on the tumor microenvironment, may dissect novel mechanisms underlying human tumorigenesis and identifies next-generation anti-cancer therapeutics. In this review, we discuss advances in our understanding of m6A RNA modification since its discovery in the 1970s to the latest progress in defining its potential clinic relevance. We summarize the molecular basis and roles of m6A regulators in the hallmarks of GI cancer and discuss their context-dependent functions. Furthermore, the identification and characterization of inhibitors or activators of m6A regulators and their potential anti-cancer effects are discussed. With the rapid growth in this field there is significant potential for developing m6A targeted therapy in GI cancers.

Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities

Emerging roles of m6A RNA modification in cancer therapeutic resistance

Biological and pharmacological roles of m6A modifications in cancer drug resistance

The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy

Surmounting Cancer Drug Resistance: New Insights from the Perspective of N6-methyladenosine RNA Modification

The role of m6A methylation in therapy resistance in cancer

m6A Modification in Non-Coding RNA: The Role in Cancer Drug Resistance

Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance

Writers, readers, and erasers RNA modifications and drug resistance in cancer

N6-methyladenosine (m6a) As a Regulator of Carcinogenesis and Drug Resistance by Targeting Epithelial-Mesenchymal Transition and Cancer Stem Cells

N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications

RNA N6-methyladenosine modification in regulating cancer stem cells and tumor immune microenvironment and its implication for cancer therapy

Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance

RNA N-6-methyladenosine Enzymes and Resistance of Cancer Cells to Chemotherapy and Radiotherapy.

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Targeting the RNA M6a Modification for Cancer Immunotherapy

Aberrant RNA M6a Modification in Gastrointestinal Malignancies: Versatile Regulators of Cancer Hallmarks and Novel Therapeutic Opportunities

Role of N6-methyladenosine RNA modification in cancer

The Emerging Role of N6-Methyladenosine RNA Methylation as Regulators in Cancer Therapy and Drug Resistance

RNA M6a Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications.

M6a Modification: a New Avenue for Anti-Cancer Therapy